BioDelivery Files BEMA Fentanyl NDA For Breakthrough Cancer Pain
This article was originally published in The Pink Sheet Daily
Commercial partner Meda has 450 specialty reps at the ready for late 2008 launch of the fast-dissolving buccal pain therapy, BDSI CEO Sirgo says.
You may also be interested in...
Meda also acquires MedPointe’s 500-strong U.S. sales force in the deal.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.